-
Express | Breaking through the toxicity limit of immune combination therapy, the innovative CTLA-4 antibody/Keytruda clinical trial is about to start
Time of Update: 2021-06-01
(MSD) to evaluate its tumor-selective research anti-CTLA-4 monoclonal antibody XTX101, and Merck’s anti-PD-1 therapy Keytruda ( Pembrolizumab) combined with the safety and efficacy of the treatment of patients with solid tumors.
-
Professor Yin Yongmei, Zhang Xizhi, Guo Zhaoji: Combined therapy with piperacillide, prolonging the survival of patients is no longer a dream
Time of Update: 2021-06-01
In the era of endocrine targeted therapy for breast cancer, as the first CDK4/6 inhibitor to be marketed in China, whether it is a randomized controlled trial (RCT) or a real world study (RWS), it has accumulated abundant evidence-based medical evidence , And promoted the update of the "Guidelines for the Standardized Diagnosis and Treatment of Advanced Breast Cancer in China (2020 Edition)", which has attracted the attention of experts in multiple disciplines.
-
JTO: Study on the prognostic value of KRAS G12C mutation in non-small cell lung cancer (NSCLC): from the European Thoracic Tumor Group's Lung Cancer Database Project
Time of Update: 2021-06-01
Recently, a research team from abroad used the European Thoracic Cancer Group (ETOP) Lungscape database (iBiobank) to conduct a study to evaluate the prognostic effect of KRAS G12C mutation in non-small cell lung cancer (NSCLC).
Among adenocarcinoma patients , the median time to relapse (TTR) of patients with Kr_G12C mutation was 66.
-
Harvard Research | Drinking these two types of drinks frequently after suffering from breast cancer is associated with a lower risk of death
Time of Update: 2021-06-01
A recent study published in the British Journal of Cancer added evidence for an association between drinking tea or coffee and a reduced risk of death among breast cancer survivors.
-
Express | Jianzhi T-cell therapy treatment of two major obstacles to solid tumors, Xinrui plans to 150 million US dollars IPO
Time of Update: 2021-06-01
▎The content team editor of WuXi AppTec today, Lyell Immunopharma (hereinafter referred to as Lyell), which is committed to developing innovative T-cell therapies for the treatment of solid tumors, submitted relevant documents to regulatory agencies and plans to log on to Nasdaq and raise US$150 million in funding.
-
The power of selecting "Ze" | Dialogue with Professor Xue Wei: "The front is moving forward", Abiraterone is expected to benefit more prostate cancer patients
Time of Update: 2021-06-01
Professor Xue Wei, director of the Department of Urology, Renji Hospital, Shanghai Jiaotong University School of Medicine, as an administrative leader, is also deeply involved in the diagnosis, treatment and research of prostate cancer.
-
Angiogenesis: a plasma biomarker that can predict the risk of bevacizumab-induced hypertension
Time of Update: 2021-06-01
Using the best cut point for each protein, the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of hypertension are estimated.
1007/s10456-021-09799-1">Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance) .
-
JAMA Sub-Journal: Delayed surgery will significantly increase the risk of recurrence in patients with non-small cell carcinoma!
Time of Update: 2021-06-01
According to the " Standards for Diagnosis and Treatment of Primary Lung Cancer (2018 Edition)", the five-year survival rate of NSCLC patients in China is only about 5% , and the current status of treatment needs to be improved.
-
Six tumor vaccines and their advantages and disadvantages
Time of Update: 2021-06-01
Therefore, a large number of tumor antigens are presented in the immune system, and APCs such as DCs activate T cells to produce anti-tumor immunity.
DCs cells loaded with tumor antigens can directly activate T cells, cause cell activation, and produce anti-tumor immunity.
-
Prof. Yanru Xie: Application of TKI drugs in HER2-positive breast cancer patients
Time of Update: 2021-06-01
Yimaitong: Could you please tell us, for patients with HER2-positive advanced breast cancer who have failed trastuzumab treatment, do you prefer macromolecular monoclonal antibody therapy or TKI?
-
J Urol: The effect of muscle reduction obesity on the prognosis of patients with urinary system cancer
Time of Update: 2021-06-01
Muscle reduction obesity is an important public health problemPrevious studies have shown that sarcopenia may predict the poor prognosis of patients with urinary system cancer.
05); other studies showed that sarcopenia obesity was a poor prognostic factor for CSS in patients with urinary system cancer (HR 5.
-
2021 ASCO Prospects | The first human study of the new BCL-2 inhibitor lisaftoclax in the treatment of R/R CLL and other hematological malignancies
Time of Update: 2021-06-01
Professor Sikander Ailawadhi and others in the United States conducted the world’s first phase I dose study to evaluate the safety and pharmacokinetics of lisaftoclax in the treatment of patients with relapsed and refractory chronic lymphocytic leukemia (R/R CLL) and other hematological malignancies (PK), pharmacodynamics (PD), efficacy and maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D).
-
EGFR 20ins ushered in the approval of the first targeted drug, and many new stars will be unveiled at 2021ASCO!
Time of Update: 2021-06-01
The CHRYSALIS study is a multi-center, open-label, multi-cohort trial that evaluated the efficacy and safety data of Amivantamab as a single agent and the combined EGFR T790M inhibitor Lazertinib in the treatment of advanced NSCLC in adults.
-
An overview of the article: 2021 V1 version of the NCCN guidelines for gastric cancer update points
Time of Update: 2021-06-01
GAST-B 1 of 6-Principles of Pathological Examination and Biomarker Detection Table 1 Update For biopsy tissue samples, endoscopic mucosal resection samples, gastrectomy samples, pathological examination analysis/reports are newly added: For all newly diagnosed patients , It is recommended to conduct a comprehensive test: MSI detection by PCR / MMR detection by IHC.
-
JAMA's latest guidelines: Colorectal cancer tends to be younger, and the starting age for screening drops to 45 years old
Time of Update: 2021-06-01
Recently, the US Preventive Services Task Force (USPSTF) released the latest colorectal cancer screening guidelines in JAMA.
At the same time, from 2000-2002 to 2014-2016, the incidence of colorectal cancer among people aged 40-49 has increased.
-
Professor Gao Beili: Comprehensive treatment + full management help ALK-positive NSCLC patients to survive better and longer
Time of Update: 2021-06-01
"Chinese treatment guidelines for lung cancer brain metastases" (2021 edition) pointed out [6]: Compared with pemetrexed combined with platinum chemotherapy, crizotinib has the control rate of intracranial metastases in patients with ALK fusion gene-positive NSCLC brain metastases Higher, but compared with the second-generation ALK-TKIs, the efficacy of intracranial metastases is not good.
-
J Urol: The benefits of neoadjuvant chemotherapy before cystectomy on the pathological staging and survival prognosis of muscle-invasive bladder cancer
Time of Update: 2021-06-01
In conclusion, neoadjuvant chemotherapy is associated with the down-regulation of the pathological staging of MIBC of all histological variants, as well as the improvement of OS in patients with UC, sarcomatoid UC, and neuroendocrine cancer .
-
Br J Cancer: TP53 mutation increases radiotherapy resistance of rhabdomyosarcoma and Ewing's sarcoma
Time of Update: 2021-06-01
In this study, the researchers aimed to determine the TP53 mutation status and related clinical phenotypes of p53 signaling pathway changes in RMS and ES patients undergoing radiotherapy.
-
Lancet oncol: Atolizumab combined with bevacizumab can significantly improve the quality of life reported by patients with advanced liver cancer
Time of Update: 2021-06-01
Compared with sorafenib, atuzumab combined with bevacizumab treatment can reduce the risk of deterioration of the predetermined EORTC QLQ-C30 general cancer symptom scale and also reduce three EORTC QLQ-HCC18 disease-specific symptom scales Risk of deterioration of two of themIn summary, a scheduled analysis of PRO data shows that compared with sorafenib, patients treated with atolizumab combined with bevacizumab have reported clinically significant benefits in terms of quality of life, function, and disease symptoms.
-
Data comparison of 21 countries in the past 20 years: the difference is too big!
Time of Update: 2021-06-01
▲In countries where screening programs (A) have been implemented early and screenings have become widespread in recent years (B), the age-standardized incidence rate (blue line-male, red line-female) and mortality rate (green line-) of colorectal cancer Male, purple line-female) change trend.
